

Bradley G. Somer, M.D.
CURRICULUM VITAE



EDUCATION & TRAINING:

- 9/89-6/92 Yeshiva University
New York, New York
BA degree in Philosophy Graduated Cum Laude with honors
in May 1992
- 8/92-6/96 Albert Einstein College of Medicine
Bronx, New York
MD degree in 1996 With "Distinction in Cardiovascular
Research"
- 5/98-6/99 Wharton Management Program, Wharton School of
Business-took several core business courses

Postgraduate Training and Fellowship Appointments:

- 6/96-6/97 Medical Internship, Hospital University of Pennsylvania,
Philadelphia, PA
- 6/97-6/98 Resident in Medicine, Hospital University of Pennsylvania,
Philadelphia, PA
- 6/98-6/02 Fellow, Hematology-Oncology, University of Pennsylvania
Cancer Center, Hospital University of Pennsylvania,
Philadelphia, PA

Faculty Appointments:

- 1/12-present Assistant Professor, University of Tennessee Health Science
Center, Division Hematology-Oncology
- 6/97-6/98 Assistant Instructor, Department of Medicine-University of
Pennsylvania
- 6/98-6/02 Assistant Instructor, Department of Medicine, Division of
Hematology-Oncology, University of Pennsylvania

Specialty Certification:

- | | |
|------|--|
| 1999 | Diplomate, American Board of Internal Medicine |
| 2002 | Diplomate, American Board of Oncology |

HONORS AND SCHOLARSHIPS:

- | | |
|--------------|---|
| 2002-2003 | Leukemia-Lymphoma Society- Man of the Year Award, Mid-South |
| 2000 | Ortho-Biotech, Annual Fellowship Award |
| 1999 | Amgen, Annual Fellowship Award |
| 1997-Present | The William Osier Society of Fellows in Medicine |
| 1996 | Alpha Omega Alpha |
| 1996 | Edward Weinstein Memorial Award for Outstanding Scholarship. Devotion To Patient Care, and Concern For Colleagues |
| 1996 | Zelig A. Rosen Memorial Award for Excellence in Cardiology |
| 1995 | Rock Sleyster Memorial AMA Scholarship nominee, 1 of 2 students nominated from the entire AECOM class of '96 |
| 1993-96 | Alan and Ruth Borenstein Medical Scholarship |
| 1992-96 | Bora Laskin Scholarship |
| 1992 | Cum Laude, Yeshiva University |
| 1989-92 | Dean's List, Yeshiva University |
| 1988 | Ontario Academic Scholarship |

PROFESSIONAL SOCIETY MEMBERSHIPS:

American Society of Clinical Oncology
American Society Hematology

PROFESSIONAL COMMITTEES AND ACTIVITIES:

2012- Present	Comprehensive Cancer Center- Executive Council
2012- Present	Methodist LeBonheur Hospital, PSA Committee- Oncology Service Line
2012	National Comprehensive Cancer Network (NCCN) Guidelines Renal And Testicular Cancer Committee
2010-Present	Quality Committee, The West Clinic
2006-Present	Guideline Committee, Chair, The West Clinic
2005-Present	Executive Committee, The West Clinic
2003-Present	Cancer Committee, Baptist Memorial Hospital
2003-Present	Cancer Committee, St. Francis Hospital
2003-2004	Chairman, Colon Cancer Task Force-American Cancer Society, Memphis/Shelby County Unit

PROFESSIONAL EXPERIENCE:

7/02-Present	Physician, Hematology-Oncology The West Clinic 100 N. Humphreys Boulevard Memphis, TN 38120
7/07-Present	ACORN Research, LLC- GU Tumor Committee Chair
7/98-02	Hospital University Of Pennsylvania Fellow Division Of Hematology-Oncology

- 3/98-02 *VeriMed Healthcare Network*, Co-Founder.
Formed Network Of Over 300 Physicians From Top
Academic Institutions To Produce Healthcare Educational
Material, Information And Communication Services. The
Organization Continues To Produce High Quality Medical
Information.
- 6/97-02 Private Consulting
Several Major Pharmaceutical Companies, Biotech Funds
And Investment Firms Consulted For Lntacorp/CIGNA,
National Board Of Medical Examiners, Educational
Commission For Foreign Medical Graduates.
- 3/00-01 Cybermedtrials.org, Director.
Leading Clinical Trials Search And Match Web Site.
- 7/97-7/00 Part-time Staff Physician
Various Medical Centers Including Methodist Hospital,
Hospital University Of Pennsylvania ER, Presbyterian
Medical Center Cardiac Unit, University Of Pennsylvania
Student Health Services, Doylestown Hospital Inpatient
Services.
- 6/96-6/98 Hospital University Of Pennsylvania- Resident
Department of Medicine
- 7/90-7/91 OHEL- Group Home For Mentally Retarded
Group Leader/Weekend Supervisor
- Summer 88 & 89 HASC Summer Program For Mentally Retarded
Supervisor/Counselor

HOSPITAL EXPERIENCE:

Active Attending Staff, Baptist Memorial Hospital, Memphis, TN
Active Attending Staff, Baptist Memorial Hospital, Desoto, Southaven, MS
Active Attending Staff, St. Francis Hospital, Memphis, TN
Consulting Staff, Methodist Germantown, Memphis, TN
Consulting Staff, Methodist University Hospital, Memphis, TN

PUBLICATIONS:

Journal Articles

Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel Arthur C Houts, PhD,^a Daniel Hennessy, PhD,^b Mark S Walker, PhD,^a Leonardo Nicacio, MD,^b Stephen F Tompson, MS,^b Paul JE Miller, PhD,^a and Bradley G Somer, MD^c ^aACORN Research LLC, Memphis, Tennessee; ^bSanofi US LLC, Bridgewater, New Jersey; and ^cTe West Clinic, Memphis, Tennessee

Deutsch A, Frishman W, Sukenik D, Somer B, Youssri A: Atrial Natriuretic Peptide and its Potential Role in Pharmacotherapy. *J Clin Pharmacology* 1994, 34:1133-47.

Feinfeld D, Guzik H, Carvounis C, Lynn R, Somer B, Aronson M, Frishman W.: Sequential Changes in Renal Function Tests in the Old: Results From the Bronx Longitudinal Aging Study. *J Am Geriatrics Soc* 1995; 43:412-4.

Somer BG, Keller SI, Frishman WH, Wassertheil-Smoller S: Value of electrocardiographic nonspecific ST and T-wave changes for predicting cardiovascular morbidity and mortality in the elderly: A report from the Bronx Aging Study. *The J of Noninvasive Card* 1998; 11(1V):12-17.

Keller SI, Somer BG, Frishman WH, Wassertheil-Smoller S: Value of electrocardiographic left axis deviation for predicting cardiovascular morbidity and mortality in the elderly: A report from the Bronx Aging Study. *The J of Noninvasive Card* 1998; 11(V):13-18.

Feinfeld D, Keller S, Somer B, Wassertheil-Smoller S, Carvounis CP, Aronson M, Nelson M, Frishman W: Serum Creatinine and blood urea nitrogen over a six-year period in the very old. *Geriatric Nephrology and Urology* 1998; 8: 131-35.

Cho Y, Somer BG, Amatya A: Natriuretic peptides and their therapeutic potential. *Heart Dis.* 1999: Nov-Dec. 1(5):305-28.

Tsai DE, Hardy, CL, Somer BG, Oloff KM, Kotloff RM, Tomaszewski JE, Montone KT, Stadtmauer EA: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder (PTLD): analysis of prognostic variables and long term follow-up of 42 patients. *Transplantation* 2001;71:1076-88.

Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ: Improvement in Sjogren's Syndrome following Therapy with Rituximab for Marginal Zone Lymphoma. *Arthritis Rheum* 2003 Jun 15:49(3):394-8.

Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B: An Open-Label, Multicenter, Phase 1/111 Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate

Cancer (CRPC). Clin Cancer Res. 2009 May 1;15(9):3172-6. Epub 2009 Apr 14.

Dreicer R, Garcia J, Hussain M, Rini B, Vogelzang N, Srinivas S, Somer B, Zhao YD, Kania M, Raghavan D: Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs. Dec 2011 Vol 29, Iss 6, 1141-1448.

Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty K, Figlin RA, Vogelzang NJ: Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression of vascular endothelial growth factor-targeted therapy. Cancer. Vol 118, Issue 24, 6055-6062, 15 Dec 2012.

Schwartzberg LS, Wang G, Somer BG, Blakely J, Wheeler BM, Walker MS, Stepanski EJ, Houts AC: Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor Positive, Her2 Negative Metastatic Breast Cancer. Submitted 5/13 to Clinical Breast Cancer

Wiechno P, Chłosta PL, Pikiel J, Somer BG, Mellado B, Duran I, Castellano D, Wedel S, Cervera Grau JM, Callies S, Andre V, Brown J, Hurt K, Lahn M, Stockle M, Reuter C, Heinrich B: Randomized Phase 2 Study with window Design to Evaluate Anti-tumor Activity of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for First-Line Treatment of Castrate Resistant Prostate Cancer. Submitted 7/13 to European Urology

Paweł Wiechno, Bradley G. Somer, Begoña Mellado, Piotr L. Chłosta, J.M. Cervera Grau, Daniel Castellano, Christoph Reuter, Michael Stöckle, Jörn Kamradt, Joanna Pikiel, Ignacio Durán, Steffen Wedel, Sophie Callies, Valérie André, Karla Hurt, Jacqueline Brown, Michael Lahn and Bernhard Heinrich

Accepted 24 October 2013, Published online 6 November 2013

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Lee S. Schwartzberg,¹ Grace Wang,² Bradley G. Somer,¹ L. Johnetta Blakely,³ Benton M. Wheeler,¹ Mark S. Walker,⁴ Edward J. Stepanski,⁴ Arthur C. Houts⁴
Clinical Breast Cancer, Vol. 14, No. 1, 13-9^a 2014

Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. ASCO Meeting Abstracts 2013;31:291. *ClinicalTrials.gov* registration number: NCT01231581.

Abstracts/Posters

C.C. Croot, M.A. Johnston, M.S. Steiner, M.L. Hancock, B.G. Somer
Effect of enobosarm, a selective androgen receptor modulator, in NSCLC patients with muscle wasting in a Phase IIb trial.

A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. (ASCO GI 2013).

Somer BG, Keller SI, Frishman WH, Wassertheil-Smoller S: Value of ECG non-Specific ST and T wave changes for predicting cardiovascular morbidity and mortality in the elderly: The Bronx Aging Study. *Am J of Geriatric Card* 1997; 6(2): 40.

Keller SI, Somer BG, Frishman WH, Wassertheil-Smoller S: Value of ECG left axis deviation for predicting cardiovascular morbidity and mortality in the elderly: The Bronx Aging Study. *Am J of Geriatr Card* 1997; 6(2): 40.

Tsai D, Hardy C, Somer B, Porter D, Schuster S, Hershock D, Laport G, Luger S, Stadtmauer: Long term outcome of 33 patients with post-transplant lymphoproliferative disorder (PTLD) following achievement of complete remission (CR). *American Society of Clinical Oncology Program/Proceedings* 2000.

Somer B, McDaid K, Tsai D, Green R, Mick R, Retter A, Porter D, Laport G, Luger S, Downs L, Stadtmauer E, Schuster S: Rituximab, ifosfamide, Mesna and etoposide (RIME) with or without mitoxantrone (RIME-N) as therapy for refractory B-cell non-Hodgkin's lymphoma. *American Society of Hematology Program/Proceedings* 2000.

Somer B, Tsai D, Leibowitz C, Hardy C, Schuster S, Luger S, Porter D, Laport G, Mangan P, Sickles C, Strobl F, Glatstein E, Stadtmauer E: Predictors of poor outcome from high-dose chemotherapy (HDC)/autologous stem cell transplant (ASCT) for Hodgkin's disease.

American Society of Clinical Oncology Programs/Proceedings 2001. (Poster Presentation)

Schwartzberg, L. S.; Kanter, L. R.; Huang, R.; Tauer, K.; Somer, B. G. Neoadjuvant Dose Dense Chemotherapy (NDDC) with Sequential Doxorubicin/Cyclophosphamide (AC) Followed by Taxane Yields High Pathologic Complete Response (pCR) Rate in II/III Breast Cancer. Poster presented at 28th Annual San Antonio Breast Cancer

Symposium. 2005 (Poster Presentation)

Liu G, Wilding G, Kelly, Kevin, Leopold L, Brill K, Somer B: Phase II, Open-Label Study of single agent AT-101 in Men with Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) levels who have not received prior chemotherapy. Prostate Cancer Symposium 2007

Curti B, Somer B, Greco FA, Brill K, Leopold L: An Open-Label, Multicenter, Phase 1/11 Study of AT-101 in Combination with Docetaxel (D) and Prednisone (P) in Men with Hormone Refractory Prostate Cancer (HRPC). 5th International Congress on Targeted Therapies in Cancer 2007.

Somer B, Schwartzberg L, Arena F, Mintzer D, Epperson A, Fu D, Fortner B: Phase II trial of nab-Paclitaxel (Nanoparticle Albumin-bound Paclitaxel: ABX) + Capecitabine (XEL) in First Line Treatment of Metastatic Breast Cancer (MBC) American Society of Clinical Oncology Programs/Proceedings 2007: (Poster Presentation) #1053

G.R. MacVicar B, Curti B, Somer B, Greco F.A., Brill K, Leopold L, Northwestern University Chicago IL, Portland Providence Medical Center Portland OR, West Clinic Memphis TN, Sarah Cannon Research Institute Nashville TN, Ascenta Therapeutics Malvern PA. An Open-Label, Multicenter, Phase 1111 Study of AT-101 in Combination with Docetaxel (D) and Prednisone (P) in Men with Hormone Refractory Prostate Cancer (HRPC). ASCO GU Symposium, Abstract 2008

MacVicar G, Greco A, Reeves J, Curti B, Poiesz B, Somer B, Maleski J, Leopold L: An Open-Label, Multicenter, Phase 1111 Study of AT-101 in Combination with Docetaxel (D) and Prednisone (P) in Men with Hormone Refractory Prostate Cancer (HRPC). 2008 EORTC Meeting, Geneva Switzerland, October 22, 2008.

Liu G, Wilding G, Kelly, Kevin, Leopold L, Brill K, Somer B: Phase 1111, Open-Label Study, Multicenter of single agent AT-101 in Men with Castrate-Resistant Prostate Cancer (CRPC). 2008

Liu G, Wilding G, Kelly, Kevin, Leopold L, Brill K, Somer B: Phase II, Open-Label Study of single agent AT-101 in Men with Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy. 2008

G. MacVicar, T. Kuzel, B. Curtis, B. Poiesz, B. Somer, F. A. Greco, V. Gressler, K. Brill, L. Leopold. An Open-Label, Multicenter, Phase 1/11 Study of AT-101 in Combination with Docetaxel (D) and Prednisone (P) in Men with Hormone Refractory Prostate Cancer (HRPC). ASCO Annual Meeting, Abstract, 2008

N.J. Vogelzang, T. E. Hutson, W. Samlowski, B. G. Somer, P. D. Richards, P. Sportelli. Phase II study of perifosine in metastatic RCC (clear and non-clear) progressing after one prior therapy (Rx) with a VEGF receptor inhibitor. Abs 302. General Poster Session.

ASCO GU, 2009

C. Higano, F. Saad, B. Somer, B. Curti D. Petrylak, C. G. Drake, F. Schnell, C. H. Redfern, D. Schrijvers. Sacks. A phase III trial of GVAX. immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Abstract LBA150. General Poster Session. ASCO GU, 2009

N. J. Vogelzang, T. E. Hutson, W. Samlowski, B. Somer, S. Richey, C. Alemany, D. Loesch, P. Richards, L. Gardner, P. Sportelli. Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. J Clin Oncol 27:15s, 2009 (suppl; abstr 5034). Poster Discussion Session, ASCO 2009.

L. Blakely, B. Somer, M. Keaton, R. Hermann, F. Schnell, P. Cobb, A. Johns, M. Walker, L. Schwartzberg. Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+ operable breast cancer. J Clin Oncol 27:15s, 2009 (suppl; abstr 595) General Poster Session, ASCO 2009

L. J. Blakely, L. S. Schwartzberg, G. Wang, B. G. Somer, B. M. Wheeler, E. J. Stepanski, M. Walker, A. Johns. Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR+ MBC). J Clin Oncol 29: 2011 (suppl; abstr e11087)

P. J. Wiechno, P. Chłosta, J. Smok-Kalwat, J. Pikilel, D. H. Henry, D. F. Christianson, B. G. Somer, B. Mellado, I. Duran, D. E. Castellano, S. Callies, V. Andre, K. Hurt, M. M. F. Lahn, M. Stöckle, C. Reuter, B. Heinrich. Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC). J Clin Oncol 29: 2011 (suppl; abstr 4592)-General poster session, ASCO 2011

W. A. Schroyens, C. L. O'Connell, M. Q. Lacy, E. C. Attar, N. Raje, B.G. Somer, F.G, Rosado, J. Hoyer, D.I. Feinstein, D.B. Sykes. TEMPI: A reversible syndrome following treatment with bortezomib. Oral and Poster Abstract ASH 2012.

P. Wiechno, P. L. Chłosta, J. Pikiel, B. G. Somer, B. Mellado, I. Durán, D. Castellano, S. Wedel, J. Cervera, S. Callies, V. André, J. Brown, K. Hurt, M. Lahn, M. Stöckle, C. Reuter, B. Heinrich. Randomized Phase 2 Study with Window-Design to Evaluate Anti-tumor Activity of the Survivin Antisense Oligonucleotide (ASO) LY2181308 in Combination with Docetaxel for First Line Treatment of Castrate-Resistant Prostate Cancer (CRPC).

Wiechno P, Chłosta PL, Pikiel J, Somer BG, Mellado B, Duran I, Castellano D, Wedel S, Cervera Grau JM, Callies S, Andre V, Brown J, Hurt K, Lahn M, Stockle M, Reuter C, Heinrich B: Randomized Phase 2 Study with window Design to Evaluate Anti-tumor

Activity of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for First-Line Treatment of Castrate Resistant Prostate Cancer. J Clin Oncol 31, 2013 (suppl; abstr 5019). 2013 ASCO annual meeting. Poster Discussion.

C.C. Croot, M.A. Johnston², M.S. Steiner², M.L. Hancock², B.G. Somer: EFFECT OF ENOBOSARM, A SELECTIVE ANDROGEN RECEPTOR MODULATOR, IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH MUSCLE WASTING IN A PHASE IIB TRIAL. Abstract selected for poster discussion, European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 5/13

Houts AC, Hennessy D, Walker MS, Nicacio L, Thompson SF, Miller PJ, Somer, BG: Community Oncology Patterns and Clinical Effectiveness in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients who Progressed after Docetaxel. Submitted as abstract to ASCO Quality Care Symposium Nov, 2013.

Jeffrey R. Infante, Bradley G. Somer, Joon Oh Park, Chung-Pin Li, Max E. Scheulen, Saifuddin M. Kasubhai, Do-Youn Oh, Yuan Liu, Soumi Lahiri, Klaudia Steplewski, Ngocdiep Le: A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. J Clin Oncol 30: 2012 (suppl 34; abstr 291) General Poster Session, 2013 Gastrointestinal Symposium

Book Chapters

Frishman WH, Sonnenblick EH: Cardiovascular Pharmacotherapeutics, 151 ed. McGraw-Hill, 1997. Pages 573-610; 703-726. Authors: Somer BG, Frishman WH.

Oncolink Patient Guide: Colorectal Cancer. Saunders, 2003. Contributing Author.

Other Publications

1999-2003 - Assistant Editor, Oncolink, online

Many online publications in a variety of health related topics-published in Oncolink, cybermedtrials, Adam, Medcases, Medscape, and licensed throughout most top health information web sites.

Major teaching/clinical responsibilities and lectures given-available on request.

Industry Research Activity Consultant

2009-Present:

Biopath Holdings, A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome

Site PI

1. Cell Genesys G0029 (2004): A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve.
2. Genentech U2963n (2005): The National Lymphocare Study: An Observational Study of Treatment Outcomes and Prognosis in Patients with Follicular Non-Hodgkin's Lymphoma.
3. Ascenta AT-101-CS-006 (2005, now closed with IRB): An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels who Have Not Received Prior Chemotherapy.
4. Ascenta AT-101-CS-202 (2005, now closed with IRB): An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination with Docetaxel and Prednisone in Men with Hormone Refractory Prostate Cancer (HRPC).
5. BMS CA183002 (2006): A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who Are Ineligible to Receive Cisplatin-Based Therapy (VINCENT).
6. Cell Genesys G-0034 (2006): A Phase 3 Randomized, Open-Label Study of Docetaxel in Combination with CG1940 and CG8711 versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain.
7. AOI Pharmaceuticals 231 (2007): Phase II Study of Perifosine for Patients with Metastatic Carcinoma of the Kidney who have Progressed on a VEGF Receptor Inhibitor.
8. Eli Lilly H6Q-MC-S024 (2007): Phase 2 Trial of Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation, and (2) After First-Line Cytotoxic Chemotherapy.
9. ACORN AVAHRPC0607 (2007): Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) MP-Next (Mitoxantrone, Prednisone, Nexavar Trial).
10. GTx G200502 (2007, now closed with IRB): Double-Blind, Placebo- Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (Cachexia) in

- Patients with Cancer.
11. Pfizer A6181120 (2008): A multi-center, randomized, double-blind, phase 3 study of sunitinib plus prednisone versus prednisone in patients with progressive metastatic castration-resistant prostate cancer after failure of a docetaxel-based chemotherapy regimen.
 12. Eli Lilly H6Q-MC-S032 (2008): A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study with and without Enzastaurin in Combination with Docetaxel and Prednisone, Followed by Enzastaurin Maintenance as First-Line Treatment in Hormone Refractory Metastatic Prostate Cancer Patients.
 13. Novartis CAMN107AUS09 (2008): A multi-center, open-label, exploratory study of Bcr-Abl kinetics in adult patients on nilotinib with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) and a suboptimal molecular response to imatinib.
 14. Sapphire ST-ANAM-207 (2008): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC.
 15. GeminX GEM013 (2008): A Multi-Center, Open-Label, Phase II Study of Obatoclox Mesylate (GX15-070MS) in Patients with Previously Untreated Myelodysplastic Syndromes (MDS) with Anemia and/or Thrombocytopenia.
 16. ACORN AVJARCC0702 (2008): Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (RCC).
 17. Pfizer A6181109 (2009, now closed with IRB): Sunitinib Treatment of Renal Adjuvant Cancer (S-TRAC): A Randomized Double-Blind Phase 3 Study of Adjuvant Sunitinib vs. Placebo in Subjects at High Risk of Recurrent RCC.
 18. Novartis CRAD001L2202 (2009): An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.
 19. GSK PMA112509 (2009): A Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS.
 20. GSK OMB110913 (2009): A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia.
 21. Lilly H8Z-MC-JACR (2009): A Randomized Phase 2 Study of LY2181308 sodium in Combination with Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer.
 22. Cephalon C18083/2048 (2010): An Open Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL).
 23. GSK MEK113487 (2010): A Randomized, Double-Blind Placebo- Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic Cancer.

24. GSK OMB112517 (2010): A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy.
25. Astra Zeneca D4320C00015 (2010): A Phase III, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-Daily, Orally Administered ZD4054 10 mg in Non- Metastatic Hormone Resistant Prostate Cancer Patients.
26. Keryx (AOI) 343 (2010): A Phase III Randomized Double-Blind Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Refractor Advanced Colorectal Cancer.
27. Novartis CTKI258A2201 (2010): A Phase II multi-center, non- randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma.
28. AVEO AV-951-10-202 (2011): A Phase 2 and Biomarker Study of Tivozanib in Subjects with Advanced Renal Cell Carcinoma.
29. Novartis CTKI258A2302 (2011): An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.
30. ACORN ARCHES00611 (2011): A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion SFU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma.
31. GSK VEG113387 (2011): A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy.

More available upon request.